Hepatocarcinoma Clinical Trial
Official title:
Essai Clinique Pour Une Endomicroscopie Robotisée Dans la redéfinition Des Stratégies d'ExérèsE (PERSÉE) appliquée à la Chirurgie Hépatique
This study aims at assessing the feasibility of Probe-based Confocal Laser Endomicroscopy (pCLE) during laparoscopic hepatic masses resection for intra-operative characterisation of hepatic masses and surgical margins assessment.
Colorectal cancer is the third most common cancer and third leading cause of cancer deaths in
the Western countries. In France, 45.000 new patients develop colorectal cancer every year.
The liver is the most common organ targeted by CRLM, representing 50%. Approximately, 15-25%
of colorectal cancer patients have synchronous CRLM at initial workup, and 20-30% patients
sustain subsequent liver metastases within few years following diagnosis.
The strategy for colorectal cancer liver metastasis resection and liver cancer has evolved to
a parenchymatic sparing procedure. This technic aims to minimize surgical margins width while
removing the tumor. Therefore, the current standard for resection margins is a margin width
superior to 1mm. However, there is still a debate concerning the margin width. Indeed, with
modern chemotherapy, several studies reported no statistical differences in the overall
survival between R0 patients and R1 patients treated with chemotherapy. However, in order to
preserve patients from chemotherapy treatments' adverse effects an intra-operative
microscopic assessment of surgical margins should be set up in order to reduce R1 margins
occurrence.
Ex vivo study:
Surgical specimens obtained during hepatectomy will be imaged to generate an atlas of pCLE
images.
In vivo study:
Intraoperative characterization of sub-capsular hepatic masses and surgical margins will be
assessed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06041490 -
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
|
Phase 2 | |
Terminated |
NCT03956940 -
Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib
|
N/A | |
Completed |
NCT03382327 -
Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas
|
N/A | |
Recruiting |
NCT03755739 -
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
|
Phase 2/Phase 3 | |
Recruiting |
NCT06028724 -
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
|
||
Recruiting |
NCT05794048 -
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
|
N/A | |
Recruiting |
NCT04435977 -
Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT04811898 -
A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
|
Phase 1 | |
Recruiting |
NCT05311319 -
HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection
|
Phase 2 | |
Completed |
NCT05464706 -
Study on the Quality of Life (QoL) After Liver Surgery
|
N/A | |
Completed |
NCT01411579 -
Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma
|
N/A | |
Completed |
NCT02519075 -
11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
|
||
Recruiting |
NCT03356236 -
Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
|